Current position

Two Sigma Investments, LP’s Royalty Pharma Plc (RPRX) position

Reported position history, portfolio importance and verified filing changes from public SEC disclosures.

Two Sigma Investments, LPVerified through Q2 2026
Relationship snapshot

At a glance

The full verified relationship, including prior ownership episodes and exits where supported.

First reportedQ2 2022Earliest verified positive filing snapshot
Latest statusCurrent positionBased on the latest supported relationship state
Peak shares2.92MHighest verified quarter-end share count
Quarters reported16Verified quarters with shares above zero
What happened?

Two Sigma Investments, LP first reported Royalty Pharma Plc in Q2 2022. The reported position was increased and reduced across later filings. Two Sigma Investments, LP currently reports 2.92M shares. The latest verified filing showed: Bought 29.7% more.

Verified SEC history

Position over time

See the same verified relationship through reported shares, portfolio weight or reported value.

Metric

Gaps indicate periods that cannot be safely connected or where a verified corporate action changes the raw share scale. Stock price, when available, is market context and not a transaction price.

Key filing events

What changed

Latest filing plus the most meaningful reported changes. Unchanged quarters are collapsed by default.

Q2 2026
Bought 29.7% more+668.64K shares · 2.92M shares reported after the change
Filing context

Quarter-end price $56.07

Q1 2026
Bought 230.5% more+1.57M shares · 2.25M shares reported after the change
Filing context

Quarter-end price $47.97

Q3 2025
Bought 2,089.0% more+1.13M shares · 1.18M shares reported after the change
Filing context

Quarter-end price $35.28

Q2 2025
Sold 96.6% of the position−1.56M shares · 54.10K shares remained
Filing context

Quarter-end price $36.03

Q1 2025
Sold 33.4% of the position−807.39K shares · 1.61M shares remained
Filing context

Quarter-end price $31.13

Q4 2024
Sold 0.4% of the position−8.93K shares · 2.42M shares remained
Filing context

Quarter-end price $25.51

Portfolio importance

How important is Royalty Pharma Plc in Two Sigma Investments, LP’s reported portfolio?

Relative importance is measured only within the verified primary non-option reported portfolio for each quarter.

Current portfolio weight0.1%Q2 2026
Current rank#189of 5017 reported positions
Peak portfolio weight0.2%Q3 2023
Best historical rank#162Q3 2024
SEC evidence & methodology

SEC filing evidence

Market context and filing-derived values are kept separate from actual transaction prices, which 13F filings do not disclose.

Latest verified stock price$58.292026-09-24

Market context only; not an investor transaction price.

Latest filing quarter-end price$56.07Q2 2026

Derived from validated reported value and shares where supported.

Latest verified investor filingQ2 2026 · filed 2026-08-14
Open SEC filing ↗

Coverage is bounded to the institution’s top reported positions and material events rather than every security in each Form 13F. The filing reflects reportable U.S.-listed holdings, not Two Sigma’s complete trading book, models, short positions, exact trade dates or execution prices. Options are reported separately.